Is Rituximab‐induced Late‐onset Neutropenia a good prognostic indicator in lymphoproliferatve disorders?

Barclay, A.N., Wright, G.J., Brooke, G. & Brown, M.H. (2002) CD200 and membrane protein interactions in the control of myeloid cells. Trends in Immunology, 23, 285–290. Brunetti, L., Di Noto, R., Abate, G., Gorrese, M., Gravetti, A., Raia, M., Scalia, G., Pascariello, C., Camera, A. & Del Vecchio, L. (2009) CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. British Journal of Haematology, 145, 665–667. Cannizzo, E., Bellio, E., Sohani, A.R., Hasserjian, R.P., Ferry, J.A., Dorn, M.E., Sadowski, C., Bucci, J.J., Carulli, G. & Preffer, F. (2010) Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry Part B Clinical Cytometry, 78, 231–238. Chanan-Khan, A.A. & Giralt, S. (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. Journal of Clinical Oncology, 28, 2612–2624. Gorczynski, R.M. (2005) CD200 and its receptors as targets for immunoregulation. Current Opinion in Investigational Drugs, 6, 483–488. Harrington, A.M., Hari, P. & Kroft, S.H. (2009) Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma. American Journal of Clinical Pathology, 132, 60–66. Kawasaki, B.T. & Farrar, W.L. (2008) Cancer stem cells, CD200 and immunoevasion. Trends in Immunology, 29, 464–468. McWhirter, J.R., Kretz-Rommel, A., Saven, A., Maruyama, T., Potter, K.N., Mockridge, C.I., Ravey, E.P., Qin, F. & Bowdish, K.S. (2006) Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proceedings of the National Academy of Sciences of the United States of America, 103, 1041–1046. Moreaux, J., Hose, D., Reme, T., Jourdan, E., Hundemer, M., Legouffe, E., Moine, P., Bourin, P., Moos, M., Corre, J., Mohler, T., De Vos, J., Rossi, J.F., Goldschmidt, H. & Klein, B. (2006) CD200 is a new prognostic factor in multiple myeloma. Blood, 108, 4194–4197. Rawstron, A.C., Orfao, A., Beksac, M., Bezdickova, L., Brooimans, R.A., Bumbea, H., Dalva, K., Fuhler, G., Gratama, J., Hose, D., Kovarova, L., Lioznov, M., Mateo, G., Morilla, R., Mylin, A.K., Omede, P., PellatDeceunynck, C., Perez Andres, M., Petrucci, M., Ruggeri, M., Rymkiewicz, G., Schmitz, A., Schreder, M., Seynaeve, C., Spacek, M., de Tute, R.M., Van Valckenborgh, E., Weston-Bell, N., Owen, R.G., San Miguel, J.F., Sonneveld, P. & Johnsen, H.E. (2008) Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica, 93, 431–438.